SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO is heavily discussed currently, driven by a mix of political factors and immigration-related news. Community members are highlighting potential policy impacts and contract opportunities. Sentiment is divided, with some seeing long-term value and others expressing strong ethical concerns.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending as traders debate its future amid fluctuating natural gas prices and weather forecasts. Community discussions revolve around potential bullish and bearish catalysts, including winter temperatures, storage levels, and LNG exports; the leveraged nature of the ETF also sparks concerns about decay. Some traders foresee a continued rise, while others anticipate a pullback, creating a volatile environment for BOIL.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics ($KYTX) is trending due to anticipation surrounding Phase 2 data for its KYV-101 trial in stiff person syndrome, expected soon, with the community actively discussing potential positive results. Investors are weighing the risk/reward, referencing a Morgan Stanley report with an increased price target based on a favorable risk profile. Some traders note call option activity and potential early knowledge of the upcoming data release.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class B

Fox Corporation - Class B

FOX is trending due to community discussions about potential trading opportunities, particularly around upward momentum and overbought conditions as indicated by RSI. Some traders are using recent price action and moving averages to formulate entry and exit points, while others are discussing the company's legal settlements related to defamation lawsuits and potential political biases. Broader conversations touch upon the media landscape, comparisons with competitors like $WBD and $NMAX, and the impact of political events.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC ($FRMI) is trending due to significant volatility after its IPO and discussions around its business model centered around powering data centers with nuclear and gas energy. The community is debating the company's valuation, potential for growth, and the implications of a recently terminated funding agreement, while some highlight its connections to political figures and potential future contracts.

Equinox Gold Corp. is a growth-focused mining company, which engages in the exploration of gold mining properties. It operates through the following segments: Greenstone, Mesquite, Castle Mountain, Los Filos, Aurizona, Fazenda, RDM, Santa Luz, and Corporate. The company was founded by Marc Pais on March 23, 2007, and is headquartered in Vancouver, Canada.

Equinox Gold Corp

Equinox Gold is trending following the announcement of the sale of its Brazil operations, a deal expected to bring in over $1 billion and allow the company to focus on North American growth. The community is speculating on how the funds will be used, with debt reduction and potential expansion of the Los Filos mine in Mexico being key talking points. Some investors are also pointing to rising gold prices as a potential tailwind for the company.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending due to a mix of factors, including recent price declines and discussions around its potential as an AI infrastructure play. Community members are debating whether the stock is oversold or fairly valued, while also keeping an eye on potential catalysts and the broader AI sector. Comparisons to peers and discussions around upcoming earnings and potential deals are contributing to the heightened interest.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending due to ongoing discussions around its China market strategy and potential outcomes from the Hikma patent infringement case. Community members are analyzing recent company communications, particularly those addressing stakeholder questions around China's NRDL and strategic opportunities.  Additionally, some are focused on the science behind IPE and its benefits beyond triglycerides, while others speculate about potential acquisitions.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending as investors debate its potential amid Bitcoin's volatility and its transition towards AI data centers, with some citing concerns over management and dilution while others point to oversold conditions and potential for a short squeeze. The stock's correlation with Bitcoin's price movements and overall market sentiment remains a key point of discussion, with community members actively sharing bullish and bearish perspectives.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation around potential cannabis rescheduling under the Trump administration, with community members discussing the possibility of a short squeeze and significant price gains. The enthusiasm is fueled by anticipation of eased regulations, tax benefits, and increased institutional investment in the cannabis sector. However, some caution against hype, pointing out previous false alarms and potential dilutions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The FDA designation expands Atossa’s investigational therapy into rare pediatric neuromuscular disease.</li><li>The program could become eligible for a Priority Review Voucher upon future approval.</li><li>Preclinical data remains encouraging, with the therapy not limited to exon-specific targeting.</li></ul>Shares of Atossa Therapeutics (ATOS) rose 10% on Thursday after the company said the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to its investigational therapy (Z)-Endoxifen for Duchenne Muscular Dystrophy.<h2 class="st-heading-2">Potential For Priority Review Voucher</h2>The company said the designation expands the program into rare pediatric neuromuscular disease and may qualify Atossa for a Priority Review Voucher (PRV) upon future approval.&nbsp;The Rare Pediatric Disease designation is reserved for serious or life-threatening conditions affecting individuals from birth to 18 years old. Atossa noted that FDA authority to award new vouchers may lapse unless renewed, with pending U.S. legislation seeking to extend the program through 2029.Janet Rea, Senior Vice President of Research and Development, said emerging preclinical data is encouraging and noted that (Z)-Endoxifen does not target specific genetic errors, potentially allowing broader applicability.<h2 class="st-heading-2">Last Week’s FDA Interaction</h2>Last week, Atossa completed a Type C meeting with the FDA to review regulatory strategy for advancing (Z)-Endoxifen across metastatic disease, neoadjuvant treatment and breast cancer risk-reduction settings. The FDA provided feedback on expedited regulatory pathways, clinical development design and endpoint strategy that the company said could support a streamlined registrational approach.CEO Steven Quay said the meeting allowed the company to incorporate FDA input into development planning and could shorten its regulatory timeline. Rea said the clinical program is now supported by data from nearly 800 participants enrolled across multiple trials.<h2 class="st-heading-2">Drug Targets Key Cancer Pathways</h2>(Z)-Endoxifen is a medicine designed to block and break down estrogen receptors, including in tumors that no longer respond to other hormone treatments. It also acts on another cancer-related pathway called protein kinase C beta 1.Atossa is developing an oral version of the drug that passes through the stomach without being changed. This prevents some of the active form from turning into an inactive form and helps keep the drug working as intended.Clinical studies in nearly 800 adults, including both healthy volunteers and people with breast cancer, have shown the drug to be well tolerated at doses up to 360 mg per day, with no maximum tolerated dose identified.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Atossa was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:974/145;" src="https://news.stocktwits-cdn.com/atos_ss_png_38ed63cfce.webp" alt="atos ss.png" width="974" height="145"><figcaption>ATOS sentiment and message volume as of December 11| Source: Stocktwits</figcaption></figure>One bullish user said compliance might still be achievable given Atossa’s current position, though they noted it would depend on the stock staying above $1 or on fresh fund inflows.<stembedurl>https://stocktwits.com/saruribbon/message/638865009</stembedurl>Another user said they were “100% confident we get fda fast track for p3 [phase 3].”&nbsp;<stembedurl>https://stocktwits.com/Mrwwonka/message/638864270</stembedurl><a href="https://stocktwits.com/symbol/ATOS">Atossa’s stock</a> has declined 3.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Atossa Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track

The FDA’s designation broadens Atossa’s development pathway in DMD and could make the program eligible for a Priority Review Voucher.

Equity

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for...

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen Atossa Therapeutics Announces Issuance of...

Ascendiant Capital Markets Forecasts Strong Price Appreciation for Atossa Genetics (NASDAQ:ATOS) Stock

Ascendiant Capital Markets lifted their price objective on Atossa Genetics from $7.75 to $8.00 and gave the company a "buy" rating in a report on Monday...

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across...

Atossa Genetics Inc. (NASDAQ:ATOS) Given Average Rating of "Hold" by Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) have been assigned an average rating of "Hold" from the five analysts that are covering the company, Marketbeat.com reports. Two...

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma Insilico Medicine and...

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation Atossa...

Atossa Genetics (NASDAQ:ATOS) Posts Quarterly Earnings Results, Meets Estimates

Atossa Genetics (NASDAQ:ATOS - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07...

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update PR...

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Current Price	$0.825
Prev Close	$0.9048
Open	$0.8817
Dividend Yield	0.00%
50-Day Moving Average	$0.8783
Beta	1.23
Avg. Volume	523,529.37
PE Ratio	-3.52

52-Week High	$1.29
52-Week Low	$0.5526
Market Capitalization	$106.57M
EPS (Annual)	-$0.2026
Price to Book	2.14
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ATOS
Atossa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATOS News

ATOSAtossa Therapeutics Inc